Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Archives of Dermatological Research|October 6, 2006
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumabCarlo Pincelli, Eric Henninger, Florence Casset-SemanazMedecine Sciences : M/S|March 5, 2004
[Multiplicity of inferences in clinical trials: adjustment methods, clinical interpretation issues]Chrystel Jouan-Flahault, Florence Casset-Semanaz, Pascal MininiCurrent Medical Research and Opinion|June 7, 2008
Analytical approaches to reporting long-term clinical trial dataKim A Papp, Philippe Fonjallaz, Florence Casset-Semanaz, et al.Journal of the American Academy of Dermatology|March 31, 2019
A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasisDanka Svecova, Martin W Lubell, Florence Casset-Semanaz, et al.Clinical Therapeutics|August 19, 2007
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisGavin Giovannoni, Olga Barbarash, Florence Casset-Semanaz, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 17, 2015
Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15Ludwig Kappos, Jens Kuhle, Juha Multanen, et al.The Lancet. Neurology|February 8, 2014
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThomas P Leist, Giancarlo Comi, Bruce A C Cree, et al.The Lancet. Neurology|December 8, 2011
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trialGiancarlo Comi, Nicola De Stefano, Mark S Freedman, et al.Journal of Neurology|January 14, 2014
Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX studyMark S Freedman, Nicola De Stefano, Frederik Barkhof, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 3, 2013
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromesNicola De Stefano, Giancarlo Comi, Ludwig Kappos, et al.Pageof 2